Serum visfatin concentration in metastatic pancreatic and midgut NETs: An exploratory study

#4528

Introduction: Neuroendocrine tumours (NETs) are commonly diagnosed at advanced stages due to their diverse and often asymptomatic clinical presentation. Visfatin, an adipocytokine involved in regulating cellular energy homeostasis, inflammation, and tumorigenesis, has been investigated as a potential biomarker in several neoplasms. However, its role in NETs remains unexplored.

Aim(s): To assess whether serum visfatin concentration differentiates between different primary sites, tumour, and patient characteristics in NETs.

Materials and methods: We performed a prospective analysis of serum visfatin levels in 39 pancreatic and midgut NETs. All patients were diagnosed with metastatic or locally advanced disease and were treated with somatostatin analogues. We conducted a comparative analysis of visfatin concentrations across the study group and in subgroups based on patient and disease characteristics.

Conference:

Presenting Author:

Authors: Komarnicki P, Maciejewski A, Musiałkiewicz J, Mastorakos G, Gut P,

Keywords: visfatin, biomarker, nicotinamide phosphoribosyltransferase, NAMPT, PBEF, eNAMPT,